Profil bibliographique

Elena Menéndez

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

32Publications signalées

63Citations signalées

0Affiliations récentes

Domaines associés

Radiopharmaceutical Chemistry and ApplicationsPeptidase Inhibition and AnalysisNeuropeptides and Animal PhysiologyNeuroendocrine Tumor Research AdvancesCardiac Structural Anomalies and Repair

Publications récentes

Accès ouvert 2026 articleOpenAlex

Preclinical Evaluation of a 177Lu-Labeled Gastrin-Releasing Peptide Receptor Antagonist and Prostate Cancer Treatment with Monotherapy and in Combination with Everolimus.

Kumar Naveen, Adrianna Bilinska, Elena Menéndez, Tilman Läppchen et autres

0 citationsOpen Access CRIS of the University of Bern

Accès ouvert 2025 articleOpenAlex

A true theranostic pair – 44/47Sc-labeled GRPR antagonist shows great promise for managing prostate and breast cancer

Naveen Kumar, Adrianna Bilinska, Elena Menéndez, Tilman Läppchen et autres

5 citationsEuropean Journal of Nuclear Medicine and Molecular Imaging

2025 articleOpenAlex

Advancing Cancer Imaging and Therapy: Evaluation of a 47Sc-Labeled Gastrin Releasing Peptide Radiotracer, [47Sc]Sc-LF1, for Prostate and Breast Tumors

Naveen Kumar, Tilman Läppchen, Adrianna Bilinska, Elena Menéndez et autres

0 citationsNuclear Medicine and Biology

2025 articleOpenAlex

Prostate Cancer Treatment Using a 177Lu-labeled Gastrin-Releasing Peptide Receptor Antagonist: Monotherapy versus Combination Therapy with Everolimus

Naveen Kumar, Tilman Läppchen, Elena Menéndez, Euy Sung Moon et autres

0 citationsNuclear Medicine and Biology

2025 articleOpenAlex

Preclinical Comparison of Two Dimeric FAP Inhibitors, DOTAGA.Glu(FAPi)2 and DO3A.Glu(FAPi)2, Labeled with Gallium-68 and Lutetium-177 for Theranostic Tumor Stroma Targeting

Adrianna Bilinska, Tilman Läppchen, Naveen Kumar, Elena Menéndez et autres

0 citationsNuclear Medicine and Biology

2025 articleOpenAlex

Optimizing FAP Radiopharmaceuticals: Key Insights from a Dose Escalation Study

Adrianna Bilinska, Tilman Läppchen, Elena Menéndez, Marcel Martin et autres

0 citationsNuclear Medicine and Biology

Accès ouvert 2025 articleOpenAlex

Preclinical Evaluation of a 177 Lu-Labeled Gastrin-Releasing Peptide Receptor Antagonist and Prostate Cancer Treatment with Monotherapy and in Combination with Everolimus

Naveen Kumar, Adrianna Bilinska, Elena Menéndez, Tilman Läppchen et autres

5 citationsACS Pharmacology & Translational Science

Accès ouvert 2025 articleOpenAlex

Preclinical evaluation of DOTAGA.Glu.(FAPI)2 and DO3A.Glu.(FAPI)2 as theranostics with human dosimetry extrapolation to lutetium-177 and terbium-161 analogs

Adrianna Bilinska, Naveen Kumar, Silvano Gnesin, Tilman Läppchen et autres

5 citationsEuropean Journal of Nuclear Medicine and Molecular Imaging

2025 articleOpenAlex

From FAP biology to theranostic precision – insights from the dose escalation study

Adrianna Bilinska, Eirinaios Pilatis, Elena Menéndez, Monika Martin et autres

0 citationsNuklearmedizin - NuclearMedicine

2025 articleOpenAlex

Enhanced therapeutic potential of [177Lu]Lu-DOTAGA.Glu.(FAPi)2 and [177Lu]Lu-DO3A.Glu.(FAPi)2 in targeting FAP-positive tumors

Adrianna Bilinska, Elena Menéndez, Eirinaios Pilatis, Nitasha Kumar et autres

0 citationsNuklearmedizin - NuclearMedicine

2025 articleOpenAlex

Evaluation of 47Sc- labeled Gastrin Releasing Peptide-based Radiotracers for Prostate and Breast Cancer

Nitasha Kumar, T Laeppchen, Eirinaios Pilatis, Elena Menéndez et autres

0 citationsNuklearmedizin - NuclearMedicine

Accès ouvert 2025 articleOpenAlex

Improved FAPI-radiopharmaceutical pharmacokinetics from the perspectives of a dose escalation study

Adrianna Bilinska, Sanjana Ballal, Chandrasekhar Bal, Tilman Läppchen et autres

17 citationsEuropean Journal of Nuclear Medicine and Molecular Imaging

Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.